The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 98 | 2.1x | 20.8x | Top tier | |
Growth | 8 | -5.8% | 6.1% | Bottom tier | |
Quality | 90 | 239.5% | 6.6% | Top tier | |
Safety | 79 | 0.1x | 0.7x | Top tier | |
Capital Return | 43 | 3.68% | 2.02% | Around median | |
Momentum | 33 | -37.0% | 4.1% | Bottom tier | |
Sentiment | 76 | 8 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Novo Nordisk A/S is a global leader in the healthcare sector, with its core activities and revenue sources focused on combating diabetes, obesity, and other chronic diseases such as rare diseases. The company generates its revenue primarily through the development and marketing of innovative peptide-based therapies, specifically the GLP-1 class, which includes prominent brands such as Ozempic for diabetes and Wegovy for weight management. The company's business operations are divided into two main segments: U.S. Operations and International Operations, with the latter driving geographical expansion through product launches in new markets.
In fiscal year 2025, Novo Nordisk achieved strong financial results, with total revenue reaching $309.1 billion, compared to $290.4 billion in 2024 and $232.3 billion in 2023. The company recorded a gross profit of $250.3 billion and a net income of $102.4 billion, with earnings per share (EPS) of $23.03. However, the gross margin declined to 81% in 2025 compared to 84.7% in 2024, due to depreciation and amortization costs associated with the acquisition of three manufacturing sites from Catalent, in addition to restructuring costs of approximately DKK 8 billion.
The analyst consensus for Novo Nordisk A/S shares indicates a general Buy recommendation, with an average price target set at $45 per share (which also represents the high and low target). Considering the stock's 52-week trading range of $35.12 to $78.38, the stock's valuation depends heavily on the company's ability to offset lower prices in the United States through rapid expansion in overall sales volume.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
The acquisition of the three Catalent manufacturing sites caused temporary pressure on Novo Nordisk's profitability during 2025 due to depreciation and amortization costs associated with the transaction. This, along with restructuring costs of DKK 8 billion, led to a decline in the company's gross margin to 81% compared to 84.7% in 2024. However, this investment is a strategic step to expand production capacity and secure long-term supply for Wegovy and Ozempic therapies.
The launch of oral Wegovy in the United States on January 5, 2026, achieved record success, with weekly prescriptions reaching approximately 50,000 for the week ending January 23, 2026. Interestingly, about 45,000 of these prescriptions were filled through cash-pay channels at an initial price of $199, indicating strong consumer demand independent of traditional insurance coverage. The company expects this oral option to help attract new patient segments who prefer to avoid injectable treatments.
Novo Nordisk expects a decline in adjusted sales and adjusted operating profit for 2026 of -5% to -13% in constant currencies due to several pressing factors. Foremost among these factors is the decline in realized prices in the United States due to Most Favored Nation (MFN) agreements and investments in market access channels. In addition, international sales will be negatively impacted by the patent expiration of the Semaglutide molecule in some key markets such as Canada, opening the door to generic competition.
Automated analysis for informational purposes only — not investment advice.
The results of the Phase 3 REIMAGINE 2 trials for CagriSema in treating type 2 diabetes showed significant superiority, achieving a cumulative blood sugar reduction of 1.91 percentage points and weight loss of 14.2% compared to Semaglutide. The drug's file was officially submitted to the U.S. Food and Drug Administration (FDA) in December 2025, and the company expects to receive a regulatory decision by the end of 2026 or early 2027. The company is also awaiting results from the additional REIMAGINE 1 trials in the first quarter of 2026 to confirm these positive findings.
Novo Nordisk reached an agreement with the U.S. administration to cover obesity medications, including Wegovy, under the Medicare Part D program via the CMMI pilot project, with coverage expected to begin in mid-2026. The administration expects this decision to be highly beneficial for the elderly segment, but the actual financial impact will be gradual and limited in 2026 due to the time required for physician education and administrative arrangements. The largest and most visible positive impact of this coverage is expected to appear during 2027 and beyond.